Screener
Ultragenyx Pharmaceutical RARE EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
FAQ
- What is Ultragenyx Pharmaceutical's EPS (diluted)?
- Ultragenyx Pharmaceutical (RARE) reported EPS (diluted) of -$0.90 in Q2 2026.
- How has Ultragenyx Pharmaceutical's EPS (diluted) changed year-over-year?
- Ultragenyx Pharmaceutical's EPS (diluted) increased by 23.1% year-over-year, from -$1.17 to -$0.90.
- What is the long-term trend for Ultragenyx Pharmaceutical's EPS (diluted)?
- Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's EPS (diluted) has grown at a -3.5% compound annual growth rate (CAGR), from -$6.71 to -$5.83.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Ultragenyx Pharmaceutical's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude